Upside – $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July) – $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins) – $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material) – $QSI +13% (no clear fresh catalyst identified; unusually large move …
Read in context ›Entera Bio Stock (ENTX)
Track Entera Bio stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
ENTX
Entera Bio
healthcare
$2.90
â–² +0.99 (+51.56%) past year
Market Cap
$467.61M
P/E Ratio
—
1Y Return
+51.56%
EPS (TTM)
-$0.35
Read the latest TheStreet Pro articles mentioning Entera Bio, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning ENTX yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning